Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

Imatinib mesylate (IM) is a small molecule inhibitor of protein tyrosine kinases. In addition to its direct effect on malignant cells, it has been suggested IM may activate of natural killer (NK) cells, hence exerting immunomodulatory functions. In preclinical settings, improved antitumor responses...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pautier, Patricia, Locher, Clara, Robert, Caroline, Deroussent, Alain, Flament, Caroline, Le Cesne, Axel, Rey, Annie, Bahleda, Ratislav, Ribrag, Vincent, Soria, Jean-Charles, Vassal, Gilles, Eggermont, Alexander, Zitvogel, Laurence, Chaput, Nathalie, Paci, Angelo
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2013
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601177/
https://ncbi.nlm.nih.gov/pubmed/23525192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.23079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados